Decreased immune response to pneumococcal conjugate vaccine after 23-valent pneumococcal polysaccharide vaccine in children

Sigurveig Th Sigurdardottir*, Kimberly J. Center, Katrin Davidsdottir, Vilhjalmur A. Arason, Bjorn Hjalmarsson, Ragnheidur Elisdottir, Gunnhildur Ingolfsdottir, Robert Northington, Daniel A. Scott, Ingileif Jonsdottir

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

23 Citations (Scopus)

Abstract

Background: Pneumococcal polysaccharide vaccine (PPV) is used in children at high risk of IPD. PPV is generally not considered to induce immunologic memory, whereas pneumococcal conjugate vaccines (PCVs) elicit protective antibody responses in infants and induce immunologic memory. Little is known about the characteristics of immune responses to PCV in children who previously received PCV and PPV in series. Objective: To characterize immune responses to 13-valent pneumococcal CRM197 conjugate vaccine (PCV13; serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) in children vaccinated in infancy with 9-valent pneumococcal-meningococcal C-CRM197 conjugate combination vaccine (PCV9-MnCC), followed by a toddler dose of PCV9-MnCC or 23-valent pneumococcal polysaccharide vaccine (PPV23). Methods: Children (n= 89) who received PCV9-MnCC in infancy and PPV23 or PCV9-MnCC at age 12 months in a previous (2002-2003) study were vaccinated at age 7.5 years with PCV13; groups PPV23/PCV13 (n= 50) and PCV9/PCV13 (n= 39). Immunoglobulin (Ig)G antibodies, avidity, and opsonophagocytic activity (OPA) were measured before and at 1 and 4 weeks postvaccination. Results: One week postvaccination, IgG levels increased significantly for all serotypes in both groups, and >97% of vaccinees achieved IgG ≥0.35. μg/ml 4 weeks after PCV13 vaccination. The PCV9/PCV13 group had higher IgG responses compared with the PPV23/PCV13 group. The upper limits of the 95% confidence intervals of the PPV23/PCV13:PCV9/PCV13 IgG geometric mean concentration ratios were <1.0 for serotypes 1, 4, 5, 9V, 18C, and 23F at 1 week. OPA and avidity results supported these findings. Conclusions: PPV23 vaccination of toddlers may compromise subsequent responses to pneumococcal conjugate vaccines. The clinical relevance of this finding is unclear.

Original languageEnglish
Pages (from-to)417-424
Number of pages8
JournalVaccine
Volume32
Issue number3
DOIs
Publication statusPublished - 9 Jan 2014

Bibliographical note

Funding Information:
We acknowledge the work of our study nurses and secretary at the Center for Child Health Services, The Primary Health Care of the Reykjavik Capital Area, Iceland; and Siggeir F. Brynjolfsson, Sindri F. Eidsson, and Stefania P. Bjarnarson at the Department of Immunology for handling all blood samples and measuring avidity. We thank all the parents and children who participated in the study. We also thank Dr Peter C. Giardina of Pfizer Inc for his support of laboratory assays and review of the manuscript, and Dr William C. Gruber of Pfizer Inc, for his contributions to data interpretation and thoughtful review of the manuscript. Editorial support was provided by Vicki Schwartz, PhD, at Excerpta Medica and was funded by Pfizer Inc.

Other keywords

  • Antibody persistence
  • Conjugate vaccine
  • Hyporesponsiveness
  • Memory
  • Pneumococcus
  • Polysaccharide

Fingerprint

Dive into the research topics of 'Decreased immune response to pneumococcal conjugate vaccine after 23-valent pneumococcal polysaccharide vaccine in children'. Together they form a unique fingerprint.

Cite this